+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Biotechnology Market

  • ID: 1825436
  • Report
  • October 2012
  • Region: Global
  • 430 Pages
  • Taiyou Research

FEATURED COMPANIES

  • Abbott Laboratories
  • Amylin Pharmaceuticals
  • Biogen Idec
  • CSL Limited
  • Genzyme Corporation
  • LifeCell Corporation
Biotechnology has become the foundation on which the pharmaceutical industry and many others are progressing on. The biotech revolution has surpassed the IT revolution as well and has become the new engine of the global economy.

The products derived through biotechnology have altered the landscape of many industries, particularly pharmaceuticals. The completion of the Human Genome Project has been a huge milestone in the biotechnology industry as it has become possible to derive treatments for many life threatening diseases, which was earlier not possible.

With the many advances in biotechnology is being fuelled by venture capital investment along with investment by governments. Incentives to boost the growth of the biotech industry have become common in almost every country.

Taiyou Research presents an analysis of the Global Biotechnology Market in its cutting-edge report which covers 24 countries and 62 companies in an in-depth analysis.

The report covers the following:

- A complete coverage of the global biotechnology market including industry definition, market profile, market statistics, industry performance, market segmentation, competition in the industry, global financing for biotechnology, and a future perspective.

- In this section itself we analyze the difference between biotech and the pharma industries as well as the significance of biotechnology as a business. Global direct investments in this industry are also analyzed.

- We analyze buyer power, supplier power, market entry, industry rivalry and presence of substitutes in keeping with Michael Porter's five forces framework analysis.

- The various applications of biotechnology in medicine, pharmacogenomics, pharmaceutical products, genetic testing, gene therapy, cloning, as well as agricultural and other applications are analyzed.

- Industry segmentation is performed based on bioinformatics, genomics, pharmacogenomics, and proteomics.

- The relation between the biotechnology industry and drug development is analyzed in our report.

- Trends and challenges of the global biotechnology industry are analyzed with the focus being on nanobiotechnology, hybrid technologies as well as emerging technologies. Challenges related to regulations, investment, public support, amongst others are analyzed comprehensively.

- The emergence and growing importance of biosimilars is looked at with regards to the importance of biotechnology in giving rise to other markets.

- Regulatory framework impacting the industry as a whole as well as the challenge of intellectual property is discussed.

- Impact of the global economic recession on the global biotech market is analyzed.

Moving on to the country analyses, we analyze the following countries in this report:

- Australia
- Belgium
- Brazil
- Canada
- China
- Cuba
- France
- Germany
- India
- Italy
- Japan
- Malaysia
- Netherlands
- New Zealand
- Pakistan
- Romania
- Singapore
- South Korea
- Spain
- Sri Lanka
- Switzerland
- Tanzania
- United Kingdom
- United States

Each country analysis includes a market profile, market statistics, future perspective, market segmentation data, as well as the impact of the recession and investment in the biotech sector.

For some countries we analyze the biotechnology market in a more in-depth perspective, including the impact of regulations on the markets, venture capital portfolios active in the market, and much more.

Moving on to an analysis of the major companies active in the global biotechnology industry, we analyze each company through a company overview, an analysis of the business segments, an analysis of their major products and services, and a SWOT analysis for each company.

This report is a comprehensive analysis of the Global Biotechnology Market and we analyze this thoroughly through our research offering – Global Biotechnology Market.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbott Laboratories
  • Amylin Pharmaceuticals
  • Biogen Idec
  • CSL Limited
  • Genzyme Corporation
  • LifeCell Corporation
1. Executive Summary

2. Introduction to the Industry
2.1 Industry Definition
2.2 Market Profile
2.3 Market Statistics
2.4 Industry Performance
2.5 Market Segmentation
2.6 Competitive Landscape
2.7 Difference between Biotech & Pharmaceutical Industries
2.8 Biotechnology as a Business
2.9 Global Financing
2.10 Global Direct Investments
2.11 Buyer Power
2.12 Supplier Power
2.13 Market Entry
2.14 Rivalry in the Industry
2.15 Presence of Substitutes
2.16 Global Biotechnology Market: Future Perspective

3. Applications of Biotechnology
3.1 Overview
3.2 Applications in Medicine
3.3 Applications in Pharmacogenomics
3.4 Development of Pharmaceutical Products
3.5 Role of Biotechnology in Genetic Testing
3.6 Role of Biotechnology in Gene Therapy
3.7 Role of Biotechnology in Cloning
3.8 Agricultural Applications
3.9 Use of Biotechnology in Bioremediation and Biodegradation

4. Industry Segmentation
4.1 Bioinformatics
4.2 Genomics
4.3 Pharmacogenomics
4.4 Proteomics

5. Biotech Industry and Drug Development

6. Trends in the Industry
6.1 Overview
6.2 Bioinformatics
6.3 Biosensor Technology
6.4 Cell Culture Technology
6.5 Cloning Technology
6.5.1 Molecular Cloning
6.5.2 Cellular Cloning
6.5.3 Animal Cloning
6.6 DNA Chip Technology
6.7 Microarrays
6.7.1 DNA Microarrays
6.7.2 Protein Microarrays
6.7.3 Tissue Microarrays
6.7.4 Whole-Cell Microarrays
6.8 Monoclonal Antibody Technologies
6.9 Nanobiotechnology
6.10 Protein Engineering Technology
6.11 Recombinant DNA Technology
6.12 Hybrid Technology
6.13 Tissue Engineering Technology

7. Challenges Facing the Industry
7.1 Overview
7.2 Globalization of the Industry
7.3 Pressure to Improve Productivity
7.4 Energy Availability
7.5 Integrity of the Supply Chain
7.6 Decoding the Causes of Diseases
7.7 Personalized Medicine
7.8 Biosimilars/Biobetters
7.9 Right to Information
7.10 Smarter & More Cooperative Regulations
7.11 New Methods of Manufacturing
7.12 Gaining the Investor Confidence
7.13 Regulatory Barriers
7.14 Issues with Patents and Intellectual Property
7.15 Financial Issues
7.16 Challenges in Developing Countries
7.17 Issues with Genetic Manipulation
7.18 Water Issues
7.19 Issues with Commercial Product Recovery
7.20 Issues with Extensive Use of Biocatalysts
7.21 Public Outcry

8. Opportunities in Biosimilars

9. Regulation and Intellectual Property in Biotechnology
9.1 Role of Regulation
9.2 Role of Public Policy in Biotech Innovation
9.3 Role of Intellectual Property

10. Impact of the Economic Recession on the Global Biotechnology Industry

11. Biotechnology Market in Australia
11.1 Market Profile
11.2 Market Segments
11.2.1 Human Therapeutics and Diagnostics
11.2.2 Agricultural Biotechnology
11.2.3 Environmental Biotechnology
11.2.4 Food Processing
11.3 Market Size
11.4 Growth Rate
11.5 Market Drivers
11.6 Regulatory Framework

12. Biotechnology Market in Belgium
12.1 Market Statistics
12.2 Market Segmentation
12.3 Competitive Landscape
12.4 Future Perspective

13. Biotechnology Market in Brazil
13.1 Market Profile
13.2 Boom in Agricultural Biotechnology
13.3 Use of Biotechnology in the Biofuels Industry
13.4 Investment in Brazil’s Biotechnology Market
13.5 Regulatory Barriers
13.6 Future Perspective

14. Biotechnology Market in Canada
14.1 Market Statistics
14.2 Market Segmentation
14.3 Competitive Landscape
14.4 Future Perspective

15. Biotechnology Market in China
15.1 Market Profile
15.2 Market Statistics
15.3 Market Segmentation
15.4 Application Sectors of Biotechnology in China
15.4.1 Biomedicine
15.4.2 Bioagriculture
15.4.3 Industrial Biotechnology
15.4.4 Bioenergy
15.4.5 Bioenvironment
15.5 Regulations Impacting the Industry
15.6 Reforms Accelerating Growth of Biotech
15.7 Impact of the Economic Recession on China’s Biotech Industry
15.8 Public-Private Sector Interaction
15.9 Venture Capital in China’s Biotechnology Market
15.10 Role of Science Parks
15.11 Competitive Landscape
15.12 Future Perspective

16. Biotechnology Market in Cuba

17. Biotechnology Market in France
17.1 Market Statistics
17.2 Market Segmentation
17.3 Competitive Landscape
17.4 Future Perspective

18. Biotechnology Market in Germany
18.1 Market Profile
18.2 Market Statistics
18.3 Market Segmentation
18.4 Competitive Landscape
18.5 Future Perspective

19. Biotechnology Market in India
19.1 Market Profile
19.2 Segment Analysis
19.2.1 Biopharmaceuticals
19.2.2 Bioservices
19.2.3 Bioagri
19.2.4 Bioindustrial
19.2.5 Bioinformatics
19.3 Reforms Accelerating Growth of Biotech
19.4 Issue of Bt Brinjal
19.5 Growth in Stem Cell Research
19.6 Emergence of Biosimilars
19.7 Impact of the Economic Recession on India’s Biotech Industry
19.8 Investment in India’s Biotechnology Market
19.9 Industry Strategies
19.9.1 Public-Private Partnerships
19.9.2 Requirement of Higher Venture Capital Funding in India
19.9.3 Moving to a Higher Value Chain
19.9.4 Enhancing Biotech Applications
19.9.5 Lucrative Domestic Market
19.9.6 Development of Skilled Manpower
19.9.7 Shortage of Manpower
19.9.8 Relationship between Pharma and Biotech Sectors
19.9.9 Boosting North-South Collaborations
19.9.10 Requirement of Innovation in Funding Models
19.9.11 Cluster Development
19.10 Future Perspective

20. Biotechnology Market in Italy
20.1 Market Statistics
20.2 Market Segmentation
20.3 Competitive Landscape
20.4 Future Perspective

21. Biotechnology Market in Japan
21.1 Market Profile
21.2 Market Statistics
21.3 Market Segmentation
21.4 Impact of the Economic Recession on Japan’s Biotech Industry
21.5 Investment in Japan’s Biotechnology Market
21.6 Competitive Landscape
21.7 Future Perspective

22. Biotechnology Market in Malaysia
22.1 Market Profile
22.2 Healthcare Biotechnology Market
22.3 Industrial Biotechnology Market
22.4 Investment in Malaysia’s Biotechnology Market
22.5 Funding Issues
22.6 Regulatory Framework
22.7 Future Perspective

23. Biotechnology Market in the Netherlands
23.1 Market Statistics
23.2 Market Segmentation
23.3 Competitive Landscape
23.4 Future Perspective

24. Biotechnology Market in New Zealand
24.1 Market Profile
24.2 Venture Capital in New Zealand’s Biotechnology Market
24.3 Angel Investment: A Latest Trend
24.4 Investment in New Zealand’s Biotechnology Market
24.5 Reforms Accelerating Growth of Biotech
24.6 Future Perspective

25. Biotechnology Market in Pakistan

26. Biotechnology Market in Romania

27. Biotechnology Market in Singapore
27.1 Market Profile
27.2 Commercial Manufacturing in Singapore
27.3 Growth in Biotech R&D
27.4 Impact of the Economic Recession on Singapore’s Biotech Industry
27.5 Future Perspective

28. Biotechnology Market in South Korea

29. Biotechnology Market in Spain
29.1 Market Statistics
29.2 Market Segmentation
29.3 Competitive Landscape
29.4 Future Perspective

30. Biotechnology Market in Sri Lanka

31. Biotechnology Market in Switzerland
31.1 Market Profile
31.2 Growth in Number of Biotech Patents
31.3 Competitive Swiss Biotech Inventions
31.4 Venture Capital in Swiss Biotechnology Market

32. Biotechnology Market in Tanzania

33. Biotechnology Market in United Kingdom
33.1 Market Profile
33.2 Market Statistics
33.3 Market Segmentation
33.4 Competitive Landscape
33.5 Future Perspective

34. Biotechnology Market in the United States
34.1 Market Profile
34.2 Market Statistics
34.3 Market Segmentation
34.4 Competitive Landscape
34.5 Biotech Financing
34.6 Reforms in US Healthcare and Impact on Biotech Companies
34.7 Future Perspective

35. Analysis of Abbott Laboratories
35.1 Company Overview
35.2 Business Segments
35.3 Major Products & Services
35.4 SWOT Analysis
35.4.1 Strengths
35.4.2 Weaknesses
35.4.3 Opportunities
35.4.4 Threats

36. Analysis of Acorda Therapeutics
36.1 Company Overview
36.2 Business Segments
36.3 Major Products & Services
36.4 SWOT Analysis
36.4.1 Strengths
36.4.2 Weaknesses
36.4.3 Opportunities
36.4.4 Threats

37. Analysis of Actelion Ltd
37.1 Company Overview
37.2 Business Segments
37.3 Major Products & Services
37.4 SWOT Analysis
37.4.1 Strengths
37.4.2 Weaknesses
37.4.3 Opportunities
37.4.4 Threats

38. Analysis of Amgen Inc
38.1 Company Overview
38.2 Business Segments
38.3 Major Products & Services
38.4 SWOT Analysis
38.4.1 Strengths
38.4.2 Weaknesses
38.4.3 Opportunities
38.4.4 Threats

39. Analysis of Amylin Pharmaceuticals
39.1 Company Overview
39.2 Business Segments
39.3 Major Products & Services
39.4 SWOT Analysis
39.4.1 Strengths
39.4.2 Weaknesses
39.4.3 Opportunities
39.4.4 Threats

40. Analysis of Astellas Pharma
40.1 Company Overview
40.2 Business Segments
40.3 Major Products & Services
40.4 SWOT Analysis
40.4.1 Strengths
40.4.2 Weaknesses
40.4.3 Opportunities
40.4.4 Threats

41. Analysis of AstraZeneca Plc
41.1 Company Overview
41.2 Business Segments
41.3 Major Products & Services
41.4 SWOT Analysis
41.4.1 Strengths
41.4.2 Weaknesses
41.4.3 Opportunities
41.4.4 Threats

42. Analysis of Biocon Limited
42.1 Company Overview
42.2 Business Segments
42.3 Major Products & Services

43. Analysis of Biogen Idec
43.1 Company Overview
43.2 Business Segments
43.3 Major Products & Services
43.4 SWOT Analysis
43.4.1 Strengths
43.4.2 Weaknesses
43.4.3 Opportunities
43.4.4 Threats

44. Analysis of Celgene Corporation
44.1 Company Overview
44.2 Business Segments
44.3 Major Products & Services
44.4 SWOT Analysis
44.4.1 Strengths
44.4.2 Weaknesses
44.4.3 Opportunities
44.4.4 Threats

45. Analysis of Cephalon Inc
45.1 Company Overview
45.2 Business Segments
45.3 Major Products & Services
45.4 SWOT Analysis
45.4.1 Strengths
45.4.2 Weaknesses
45.4.3 Opportunities
45.4.4 Threats

46. Analysis of Crucell NV
46.1 Company Overview
46.2 Business Segments
46.3 Major Products & Services
46.4 SWOT Analysis
46.4.1 Strengths
46.4.2 Weaknesses
46.4.3 Opportunities
46.4.4 Threats

47. Analysis of CSL Limited
47.1 Company Overview
47.2 Business Segments
47.3 Major Products & Services
47.4 SWOT Analysis
47.4.1 Strengths
47.4.2 Weaknesses
47.4.3 Opportunities
47.4.4 Threats

48. Analysis of Cubist Pharmaceuticals
48.1 Company Overview
48.2 Business Segments
48.3 Major Products & Services
48.4 SWOT Analysis
48.4.1 Strengths
48.4.2 Weaknesses
48.4.3 Opportunities
48.4.4 Threats

49. Analysis of Daiichi Sankyo
49.1 Company Overview
49.2 Business Segments
49.3 Major Products & Services
49.4 SWOT Analysis
49.4.1 Strengths
49.4.2 Weaknesses
49.4.3 Opportunities
49.4.4 Threats

50. Analysis of Enzon Pharmaceuticals
50.1 Company Overview
50.2 Business Segments
50.3 Major Products & Services
50.4 SWOT Analysis
50.4.1 Strengths
50.4.2 Weaknesses
50.4.3 Opportunities
50.4.4 Threats

51. Analysis of Genzyme Corporation
51.1 Company Overview
51.2 Business Segments
51.3 Major Products & Services
51.4 SWOT Analysis
51.4.1 Strengths
51.4.2 Weaknesses
51.4.3 Opportunities
51.4.4 Threats

52. Analysis of Gilead Sciences Inc
52.1 Company Overview
52.2 Business Segments
52.3 Major Products & Services
52.4 SWOT Analysis
52.4.1 Strengths
52.4.2 Weaknesses
52.4.3 Opportunities
52.4.4 Threats

53. Analysis of Hoffmann-La Roche
53.1 Company Overview
53.2 Business Segments
53.3 Major Products & Services
53.4 SWOT Analysis
53.4.1 Strengths
53.4.2 Weaknesses
53.4.3 Opportunities
53.4.4 Threats

54. Analysis of ImmunoGen, Inc
54.1 Company Overview
54.2 Business Segments
54.3 Major Products & Services
54.4 SWOT Analysis
54.4.1 Strengths
54.4.2 Weaknesses
54.4.3 Opportunities
54.4.4 Threats

55. Analysis of LifeCell Corporation
55.1 Company Overview
55.2 Business Segments
55.3 Major Products & Services

56. Analysis of Mitsubishi Tanabe Pharma Corporation
56.1 Company Overview
56.2 Business Segments
56.3 Major Products & Services
56.4 SWOT Analysis
56.4.1 Strengths
56.4.2 Weaknesses
56.4.3 Opportunities
56.4.4 Threats

57. Analysis of OSI Pharmaceuticals
57.1 Company Overview
57.2 Business Segments
57.3 Major Products & Services
57.4 SWOT Analysis
57.4.1 Strengths
57.4.2 Weaknesses
57.4.3 Opportunities
57.4.4 Threats

58. Analysis of Takara Holdings
58.1 Company Overview
58.2 Business Segments
58.3 Major Products & Services
58.4 SWOT Analysis
58.4.1 Strengths
58.4.2 Weaknesses
58.4.3 Opportunities
58.4.4 Threats

59. Analysis of UCB SA
59.1 Company Overview
59.2 Business Segments
59.3 Major Products & Services
59.4 SWOT Analysis
59.4.1 Strengths
59.4.2 Weaknesses
59.4.3 Opportunities
59.4.4 Threats

60. Analysis of Vertex Pharmaceuticals
60.1 Company Overview
60.2 Business Segments
60.3 Major Products & Services
60.4 SWOT Analysis
60.4.1 Strengths
60.4.2 Weaknesses
60.4.3 Opportunities
60.4.4 Threats

61. Analysis of ViroPharma Incorporated
61.1 Company Overview
61.2 Business Segments
61.3 Major Products & Services
61.4 SWOT Analysis
61.4.1 Strengths
61.4.2 Weaknesses
61.4.3 Opportunities
61.4.4 Threats

62. Analysis of ZymoGenetics Inc
62.1 Company Overview
62.2 Business Segments
62.3 Major Products & Services
62.4 SWOT Analysis
62.4.1 Strengths
62.4.2 Weaknesses
62.4.3 Opportunities
62.4.4 Threats

63. Appendix

64. Glossary
Note: Product cover images may vary from those shown
- Abbott Laboratories
- Acorda Therapeutics
- Actelion Ltd
- Amgen Inc
- Amylin Pharmaceuticals
- Astellas Pharma
- AstraZeneca Plc
- Biocon Limited
- Biogen Idec
- Celgene Corporation
- Cephalon Inc
- Crucell NV
- CSL Limited
- Cubist Pharmaceuticals
- Daiichi Sankyo
- Enzon Pharmaceuticals
- Genzyme Corporation
- Gilead Sciences Inc
- Hoffmann-La Roche
- ImmunoGen, Inc
- LifeCell Corporation
- Mitsubishi Tanabe Pharma Corporation
- OSI Pharmaceuticals
- Takara Holdings
- UCB SA
- Vertex Pharmaceuticals
- ViroPharma Incorporated
- ZymoGenetics Inc
Note: Product cover images may vary from those shown
Adroll
adroll